(Q37982150)

26 August 2017

Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review (English)

1 reference

26 August 2017

1 reference

4

Timothy J Wilt

1 reference

26 August 2017

Mike D Shelley

1

1 reference

26 August 2017

Gabriel Jones

2

1 reference

26 August 2017

Anne Cleves

3

1 reference

26 August 2017

Malcolm D Mason

5

1 reference

26 August 2017

Howard G Kynaston

6

1 reference

26 August 2017

1 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

109

1 reference

26 August 2017

496-505

1 reference

26 August 2017

4

1 reference

26 August 2017

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Intravesical gemcitabine: a phase 1 and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Pharmacokinetic study to optimize the intravesical administration of gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10880.X

10.1111/J.1464-410X.2011.10880.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference